(HALO) Halozyme Therapeutics - Performance 49.9% in 12m
Compare HALO with Indices, Sectors and Commodities and Bonds. Who performs better in which timeframe?
Performance Rating
60.64%
#8 in Group
Rel. Strength
90.71%
#744 in Universe
Total Return 12m
49.88%
#31 in Group
Total Return 5y
150.47%
#16 in Group
P/E 17.1
55th Percentile in Group
P/E Forward 12.7
48th Percentile in Group
PEG -2.50
13th Percentile in Group
FCF Yield 5.73%
98th Percentile in Group
12m Total Return: HALO (49.9%) vs XBI (-6.5%)

5y Drawdown (Underwater) Chart

Top Performers in Biotechnology
Overall best picks of Peer Group Selected by proven GARP Predictive Metrics, sorted by Growth Rating
Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability |
EPS CAGR |
---|---|---|---|---|---|---|---|---|
UTHR NASDAQ United Therapeutics |
-8.25% | 25.2% | 163% | 11.9 | 10.6 | 1.43 | 83.8% | 78.5% |
HLN NYSE Haleon |
0.89% | 22.3% | 40.6% | 24.7 | 20.3 | 1.8 | 27.1% | - |
AMGN NASDAQ Amgen |
-11.6% | 4.69% | 33.7% | 36.6 | 13.3 | 0.94 | -18.8% | -20% |
LONN SW Lonza |
-1.09% | 7.58% | 35.2% | 60.7 | 31.7 | 1.15 | 12.6% | -10.3% |
BIM PA Biomerieux |
-2.83% | 12.9% | -1.51% | 31 | 24.2 | 1.45 | -58.7% | -25.1% |
KMDA NASDAQ Kamada |
-7.32% | 33% | -9.75% | 24.3 | 22.8 | 0.91 | 47.7% | 3.93% |
ERF PA Eurofins Scientific SE |
9.29% | -9.24% | 24.2% | 24.3 | 11.7 | 0.58 | -70.8% | -17.1% |
GRFS NASDAQ Grifols |
-7.23% | 11% | -64% | 26.9 | 11 | 0.23 | -45.4% | -33.9% |
Performance Comparison: HALO vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for HALO
Total Return (including Dividends) | HALO | XBI | S&P 500 |
---|---|---|---|
1 Month | -8.76% | -10.94% | -6.73% |
3 Months | 5.00% | -14.92% | -11.93% |
12 Months | 49.88% | -6.46% | 7.24% |
5 Years | 150.47% | -19.21% | 100.61% |
Trend Score (consistency of price movement) | HALO | XBI | S&P 500 |
1 Month | -82.5% | -52.8% | -63.5% |
3 Months | 63.6% | -92.8% | -90.3% |
12 Months | 52.9% | -32.4% | 60.6% |
5 Years | 51.3% | -53.3% | 84.2% |
Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
1 Month | #90 | 2.45% | -2.18% |
3 Month | #27 | 23.4% | 19.2% |
12 Month | #31 | 60.2% | 39.8% |
5 Years | #15 | 210% | 24.9% |
FAQs
Does HALO Halozyme Therapeutics outperforms the market?
Yes,
over the last 12 months HALO made 49.88%, while its related Sector, the SPDR S&P Biotech (XBI) made -6.46%.
Over the last 3 months HALO made 5.00%, while XBI made -14.92%.
Over the last 3 months HALO made 5.00%, while XBI made -14.92%.
Performance Comparison HALO vs Indeces and Sectors
HALO vs. Indices HALO is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
US S&P 500 | SPY | -2.56% | -2.03% | 21.8% | 42.6% |
US NASDAQ 100 | QQQ | -3.04% | -1.40% | 21.6% | 42.3% |
US Dow Jones Industrial 30 | DIA | -0.53% | -1.85% | 21.1% | 45.4% |
German DAX 40 | DAX | -3.78% | -4.82% | 1.85% | 29.6% |
Shanghai Shenzhen CSI 300 | CSI 300 | -1.99% | -5.37% | 20.6% | 40.7% |
Hongkong Hang Seng | HSI | -5.23% | -5.04% | 17.2% | 33.1% |
India NIFTY 50 | INDA | -4.71% | -10.8% | 18.4% | 46.9% |
Brasil Bovespa | EWZ | -6.83% | -9.22% | 16.7% | 58.6% |
HALO vs. Sectors HALO is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
Communication Services | XLC | -3.27% | -1.91% | 12.6% | 34.8% |
Consumer Discretionary | XLY | -4.0% | -1.92% | 16.5% | 38.6% |
Consumer Staples | XLP | -2.71% | -11.7% | 13.8% | 38.6% |
Energy | XLE | -2.63% | 3.74% | 23.1% | 62.6% |
Financial | XLF | -3.26% | -3.91% | 12.9% | 32.1% |
Health Care | XLV | -0.29% | -1.0% | 24.0% | 52.3% |
Industrial | XLI | -1.96% | -2.73% | 21.9% | 45.8% |
Materials | XLB | -2.30% | -2.91% | 29.0% | 55.8% |
Real Estate | XLRE | -2.33% | -5.53% | 22.1% | 35.2% |
Technology | XLK | -2.83% | 0.24% | 28.0% | 48.7% |
Utilities | XLU | -2.45% | -8.96% | 18.1% | 28.2% |
Aerospace & Defense | XAR | -1.11% | -5.58% | 12.4% | 28.0% |
Biotech | XBI | -5.98% | 2.18% | 33.2% | 56.3% |
Homebuilder | XHB | -4.09% | -0.64% | 36.5% | 60.4% |
Retail | XRT | -4.43% | -3.37% | 25.2% | 56.2% |